Skip to main content
Top
Published in: Hepatology International 3/2010

01-09-2010 | Original Article

Disturbances of parathyroid hormone–vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study

Authors: Arash Miroliaee, Mohsen Nasiri-Toosi, Omid Khalilzadeh, Alireza Esteghamati, Alireza Abdollahi, Mehdi Mazloumi

Published in: Hepatology International | Issue 3/2010

Login to get access

Abstract

Purpose

Liver has an important role in metabolism of vitamin D. This study aimed to evaluate the patterns of vitamin D–parathyroid hormone (PTH) disturbance and correlate it in patients with non-cholestatic chronic liver disease (CLD).

Methods

A total of 40 healthy controls and 90 consecutive patients with evidence of non-cholestatic CLD due to hepatitis C (n = 28), hepatitis B (n = 26), autoimmune hepatitis (n = 19), and cryptogenic causes (n = 17) were enrolled. Cirrhosis was evident in 51 patients. Serum concentrations of 25-hydroxy vitamin D, PTH, calcium, phosphate, and liver enzymes were measured. Child–Pugh classification was determined in cirrhotic patients.

Results

Vitamin D deficiency (<50 nmol/l) was found in 46 (51.1%) patients and vitamin D insufficiency (50–80 nmol/l) in 15 (16.7%) patients. Secondary hyperparathyroidism (serum PTH > 6.8 pmol/l) was present in 6 (6.7%) patients. The prevalence of vitamin D deficiency was significantly higher in cirrhotic versus noncirrhotic patients (76.5 vs. 17.9%; P < 0.001), whereas there was no significant difference in serum calcium, phosphate, and PTH levels. Child–Pugh class B and C patients had significantly lower vitamin D level compared with class A patients (P < 0.001), whereas there was no significant difference in serum calcium, phosphate, and PTH levels. No significant correlation was seen between vitamin D and PTH, calcium or phosphate levels. Lower serum level of vitamin D was associated with coagulopathy, hyperbilirubinemia, hypoalbuminemia, anemia, and thrombocytopenia.

Conclusions

Vitamin D inadequacy and the severity of liver dysfunction move in parallel in patients with non-cholestatic CLD. Vitamin D assessment and replacement should be considered in the management of patients with non-cholestatic CLD.
Literature
1.
go back to reference Pappa HM, Bern E, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 2008;24:176–183CrossRefPubMed Pappa HM, Bern E, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 2008;24:176–183CrossRefPubMed
2.
go back to reference Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996;31:669–678CrossRefPubMed Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996;31:669–678CrossRefPubMed
3.
go back to reference George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009;15:3516–3522CrossRefPubMed George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009;15:3516–3522CrossRefPubMed
4.
go back to reference Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998;28:695–699CrossRefPubMed Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998;28:695–699CrossRefPubMed
5.
go back to reference Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–966CrossRefPubMed Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–966CrossRefPubMed
6.
go back to reference Yenice N, Gumrah M, Mehtap O, Kozan A, Turkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol 2006;17:260–266PubMed Yenice N, Gumrah M, Mehtap O, Kozan A, Turkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol 2006;17:260–266PubMed
7.
go back to reference de Albuquerque Taveira AT, Fernandes MI, Galvao LC, Sawamura R, de Mello Vieira E, de Paula FJ. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol (Oxf) 2007;66:518–523 de Albuquerque Taveira AT, Fernandes MI, Galvao LC, Sawamura R, de Mello Vieira E, de Paula FJ. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol (Oxf) 2007;66:518–523
8.
go back to reference Duarte MP, Farias ML, Coelho HS, Mendonca LM, Stabnov LM, Do Carmo d Oliveira M, et al. Calcium–parathyroid hormone–vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001;16:1022–1027CrossRefPubMed Duarte MP, Farias ML, Coelho HS, Mendonca LM, Stabnov LM, Do Carmo d Oliveira M, et al. Calcium–parathyroid hormone–vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001;16:1022–1027CrossRefPubMed
9.
go back to reference Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 2009;200:207–221CrossRefPubMed Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 2009;200:207–221CrossRefPubMed
10.
go back to reference Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev 2008;66:S116–S124CrossRefPubMed Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev 2008;66:S116–S124CrossRefPubMed
11.
go back to reference Boyan BD, Schwartz Z. 1,25-Dihydroxy vitamin D3 is an autocrine regulator of extracellular matrix turnover and growth factor release via ERp60-activated matrix vesicle matrix metalloproteinases. Cells Tissues Organs 2009;189:70–74CrossRefPubMed Boyan BD, Schwartz Z. 1,25-Dihydroxy vitamin D3 is an autocrine regulator of extracellular matrix turnover and growth factor release via ERp60-activated matrix vesicle matrix metalloproteinases. Cells Tissues Organs 2009;189:70–74CrossRefPubMed
12.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649CrossRefPubMed Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649CrossRefPubMed
13.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470CrossRefPubMed Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470CrossRefPubMed
14.
go back to reference Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713–716CrossRefPubMed Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713–716CrossRefPubMed
15.
go back to reference Ormarsdottir S, Ljunggren O, Mallmin H, Michaelsson K, Loof L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2002;14:43–48CrossRefPubMed Ormarsdottir S, Ljunggren O, Mallmin H, Michaelsson K, Loof L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2002;14:43–48CrossRefPubMed
16.
go back to reference Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996;11:417–421CrossRefPubMed Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996;11:417–421CrossRefPubMed
17.
go back to reference Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 1989;35:225–234PubMed Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 1989;35:225–234PubMed
18.
go back to reference Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, et al. Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999;14:547–552CrossRefPubMed Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, et al. Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999;14:547–552CrossRefPubMed
19.
20.
go back to reference Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997;60:148–154CrossRefPubMed Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997;60:148–154CrossRefPubMed
21.
go back to reference Bai XL, Liang TB, Wu LH, Li DL, Geng L, Wang WL, et al. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases. Transplant Proc 2007;39:3182–3185CrossRefPubMed Bai XL, Liang TB, Wu LH, Li DL, Geng L, Wang WL, et al. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases. Transplant Proc 2007;39:3182–3185CrossRefPubMed
22.
go back to reference Uretmen S, Gol M, Cimrin D, Irmak E. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;123:67–71CrossRefPubMed Uretmen S, Gol M, Cimrin D, Irmak E. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;123:67–71CrossRefPubMed
23.
go back to reference Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007;5:513–520CrossRefPubMed Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007;5:513–520CrossRefPubMed
24.
go back to reference Adorini L. Vitamin D receptor polymorphisms in primary biliary cirrhosis: a functional connection? J Hepatol 2009;50:1071–1073CrossRefPubMed Adorini L. Vitamin D receptor polymorphisms in primary biliary cirrhosis: a functional connection? J Hepatol 2009;50:1071–1073CrossRefPubMed
25.
go back to reference Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472CrossRefPubMed Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472CrossRefPubMed
26.
go back to reference Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745–2750CrossRefPubMed Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001;96:2745–2750CrossRefPubMed
27.
go back to reference Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994;35:177–193PubMed Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994;35:177–193PubMed
Metadata
Title
Disturbances of parathyroid hormone–vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study
Authors
Arash Miroliaee
Mohsen Nasiri-Toosi
Omid Khalilzadeh
Alireza Esteghamati
Alireza Abdollahi
Mehdi Mazloumi
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 3/2010
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9194-2

Other articles of this Issue 3/2010

Hepatology International 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.